Pfizer and Stemgent to collaborate on stem cell research

Pfizer has entered into collaboration with stem cell science specialist Stemgent in a partnership designed to aid pharmaceutical research efforts.

The agreement will see Stemgent distribute research reagents developed by Pfizer with pharmaceutical modes of action sold to scientists in order to conduct experiments.

It will also see Pfizer and Stemgent collaborate to conduct an ongoing review of the partnership’s progress, including information monitoring, materials exchange and providing research guidance.

Pfizer expressed hope that this new agreement will assist stem cell research into a variety of medical fields, such as cancer treatment, metabolic disease and neuroscience.

Dr Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, said: “We are pleased to form this partnership with Stemgent. We applaud the efforts Stemgent has made in bringing important research tools to the stem cell community.”

Earlier this month, the firm entered into collaboration with MicuRx Pharmaceuticals and Cumencor Pharmaceuticals to develop a number of new tuberculosis treatments.